Host immune response against homologous challenge infection of Ancylostoma caninum larvae after application of effective anthelmintics.
The development of immunity against Ancylostoma caninum larval reinfection has been investigated in mice after the primary infection has been treated with an effective anthelmintics. Experimentally A, caninum larvae infected mice treated with levamisole (5 x 40 mg/kg), thiabendazole (5 x 200 mg/kg), oxfendazole (5 x 100 mg/kg), or albendazole (5 x 100 mg/kg) when challenged with A. caninum larvae showed 47.77 to 55.81% larval reduction from the challenge dose indicating thereby the development of partial immunity.
D015766:Albendazole; D000722:Ancylostoma / Q000276:immunology*; D000724:Ancylostomiasis / Q000188:drug therapy / Q000276:immunology*; D000818:Animals; D000871:Anthelmintics / Q000009:adverse effects*; D001562:Benzimidazoles / Q000009:adverse effects; D007109:Immunity / Q000187:drug effects; D007978:Levamisole / Q000009:adverse effects; D008297:Male; D051379:Mice; D013827:Thiabendazole / Q000009:adverse effects; D013997:Time Factors
D000871:Anthelmintics; D001562:Benzimidazoles; D007978:Levamisole; D015766:Albendazole; D013827:Thiabendazole; C011030:oxfendazole